Centrus energy research:
Centrus Energy: America's Only Path Back To Its Own Uranium Enrichment
- 1. The Thesis
- 2. Funding The American Uranium Monopoly
- 3. The Financial Paradox, Explained
- 4. Why SWU Prices Keep Rising Even As Volumes Fall
- 5. The Dual-Fuel Strategy: LEU Today, HALEU Tomorrow
- 6. Building Without Diluting
- 7. Proof It's Real, Not Just A Slide
- 8. The Other End Of The Fuel Cycle: BWX Technologies
- 9. The Uranium ETF Pullback As An Entry Signal
- 10. The Price: Two Different Risk Profiles, One Megatrend
- 11. What Could Go Wrong
- 12. Muffett's Take
1 The Thesis
Strategic energy security has quietly become one of the clearest bipartisan priorities in Washington, and nowhere is the gap between ambition and current capability wider than uranium enrichment. The United States built the technology, then let its enrichment industry atrophy for decades while Russia's Rosatom became the world's dominant supplier of enriched uranium — including to American utilities. That dependency became untenable the moment Congress banned Russian uranium imports, and it becomes more untenable every year AI data centers, grid growth, and a new generation of small modular reactors push electricity demand higher. Rebuilding domestic enrichment capacity from scratch is now a national priority with real federal dollars behind it, and there are only a small number of companies positioned to actually do the rebuilding.
Centrus Energy is the closest thing America has to an enrichment monopoly in the making — the only U.S.-headquartered company currently under contract to produce both low-enriched uranium (LEU) for today's reactor fleet and high-assay low-enriched uranium (HALEU) for the next-generation reactors being designed around it. BWX Technologies sits at the other end of the same strategic value chain: naval nuclear propulsion, government reactor components, and the manufacturing base the Navy and Department of Energy depend on. Neither company is a pure uranium-price bet. Both are picks-and-shovels plays on the U.S. government's own stated priority of rebuilding a domestic nuclear fuel and component supply chain — and both currently trade well below their own 52-week highs, inside a sector-wide pullback that we think is a timing gift rather than a warning sign.
2 Funding The American Uranium Monopoly
Centrus operates two facilities that matter enormously to this story: Piketon, Ohio, where its American Centrifuge technology is being scaled toward commercial LEU production, and Oak Ridge, Tennessee, where HALEU cascades are already producing material under a Department of Energy contract. The company isn't proposing to build this capability — it's already doing it, ahead of several of its own prior schedules, with two metric tons of HALEU produced ahead of plan and a target of twelve metric tons a year after 2030.
3 The Financial Paradox, Explained
The single most important chart in Centrus's own investor materials is also the one that best explains why this stock is volatile enough to offer a real entry opportunity.
Read only the left column and Centrus looks like a company whose margins are collapsing. Read the right column and it's a company sitting on $1.9 billion of unrestricted cash, a $4.5 billion backlog, and a $900 million DOE task order specifically earmarked to expand its Piketon enrichment capacity. Both columns are true at once, and the bridge between them is straightforward: Centrus is deliberately absorbing short-term, non-capitalized costs — engineering, security clearances, manufacturer readiness — to build a first-of-a-kind domestic enrichment facility, and GAAP accounting forces those costs through the income statement now even though the revenue they unlock arrives over the next decade-plus. That's a normal, if uncomfortable-looking, feature of building heavy industrial infrastructure from scratch, not a sign the underlying business is deteriorating.
4 Why SWU Prices Keep Rising Even As Volumes Fall
If you want a single chart that captures the supply-demand imbalance underneath this entire thesis, it's this one.
Separative work unit prices — the standard unit of enrichment services — rose 3% in the second quarter even as volumes sold fell 23%. That combination only happens in a genuine seller's market: buyers are paying more for less because there simply isn't more supply to be had, and won't be for years given 18-to-24-month lead times on new manufacturing capacity and zero new domestic enrichment capacity currently online anywhere in the country. Every demand driver on the left side of that chart — AI-driven electrification, next-generation SMRs that mostly require HALEU specifically, and reactor restarts in Europe and Asia — points the same direction, and none of them are things Centrus has to do anything to benefit from. It just has to keep building.
5 The Dual-Fuel Strategy: LEU Today, HALEU Tomorrow
Centrus isn't betting on a single fuel type or a single reactor generation, and this matrix from its own materials lays out why that matters.
LEU serves the reactor fleet that already exists and is running today — a roughly $3.7 billion backlog against strong utility demand, with commercial-scale operations targeted for 2029. HALEU serves the reactor fleet being built right now, and Centrus already has a signed letter of intent with Oklo covering five Aurora powerhouse units and, as of early August 2026, a definitive supply agreement with X-energy for its Xe-100 small modular reactor. That second deal is worth pausing on: it's not a pilot program or a memorandum of understanding, it's a definitive contract with prepayments attached, from a company actively building next-generation reactors, for fuel Centrus is already producing ahead of its own government contract schedule.
6 Building Without Diluting
A first-of-a-kind manufacturing build-out this size usually comes with one of two bad outcomes for existing shareholders: heavy debt, or heavy share dilution. Centrus's own capital structure slide argues it's avoiding both.
The legacy uranium brokerage and enrichment business is still generating real, growing cash — $153.4 million in the second quarter alone, up 22% year over year — and that cash, alongside the DOE task order and customer prepayments from Oklo and X-energy, is funding the buildout directly. Centrus has an at-the-market equity program in place, but it deployed only $53.9 million through it in the quarter against a $1.9 billion cash balance, which is a modest amount of dilution for a company self-funding a multi-billion-dollar industrial expansion.
7 Proof It's Real, Not Just A Slide
Every growth story in this sector makes claims about future capacity. What separates Centrus right now is how much of that capacity is already physically real.
Three-quarters of critical suppliers are already under finalized contract, a construction contractor is actively building a 150,000-square-foot facility, and the first commercial-scale AC100M centrifuge is on track for completion at Oak Ridge by the end of this year. That's the difference between a company promising future capacity and a company that's already pouring concrete for it — and management reaffirmed, rather than walked back, its full-year revenue and capital deployment guidance alongside all of it.
8 The Other End Of The Fuel Cycle: BWX Technologies
If Centrus is the enrichment story, BWX Technologies is the manufacturing and government-infrastructure story, and we think the two belong in the same note rather than treated as substitutes. BWXT builds precision naval nuclear reactors and components under a decades-long, sole-source relationship with the U.S. Navy, alongside a growing commercial nuclear manufacturing business. It just posted 18% revenue growth in its second quarter, with backlog up 40% year over year, and raised full-year guidance across revenue, EBITDA, and EPS. It's also actively sharpening its focus on nuclear specifically — announcing the sale of its medical business to Nordic Capital for up to $800 million in the same quarter, freeing capital and management attention to concentrate on the defense and nuclear-infrastructure buildout. BWXT recently completed the acquisition of Precision Components Group to expand its domestic nuclear manufacturing capacity, and secured a role in the Department of Energy's $17.5 billion conditional loan program supporting long-lead components for new Westinghouse AP1000 reactors.
The strategic security angle isn't abstract for either company. In July 2026, the U.S. signed a civil nuclear cooperation agreement with Saudi Arabia — the kind of allied nuclear buildout that ultimately depends on the same domestic fuel and component supply chain both of these companies are racing to expand. The Department of Energy's newly formalized Nuclear Fuel Cycle Consortium under the Defense Production Act names both companies among the group of suppliers Washington is explicitly trying to build out. This isn't two companies riding a vague nuclear theme — it's two companies named in the same federal industrial policy.
9 The Uranium ETF Pullback As An Entry Signal
You flagged the uranium ETF drawdown specifically, and the numbers back up the instinct. The Global X Uranium ETF (URA) trades around $45, down 28% from its 52-week high of $62.28; the Sprott Uranium Miners ETF (URNM) has fallen even further, down roughly 39% from its high near $85. Centrus itself is a top-ten URA holding. This is a genuine, broad-based sector pullback, not a stock-specific problem — and it's happening at the same time the fundamental data described above (rising SWU prices, record backlogs, reaffirmed guidance, a $900 million DOE task order, a signed Saudi civil nuclear agreement) has kept improving. That divergence between price action and fundamentals is exactly the setup we look for.
10 The Price: Two Different Risk Profiles, One Megatrend
These two stocks should not be sized the same way in a portfolio, and it's worth being explicit about why. Centrus (LEU) trades at $185.19, down 60% from its 52-week high of $464.25 and up 30% from its 52-week low of $142.13 — an enormous range that reflects both the excitement around its enrichment monopoly position and the market's real uncertainty about execution and funding risk. Market cap is $3.70 billion, trailing P/E is 85 times, and forward P/E is 78.5 times — expensive by any conventional measure, on a company management itself says has years of J-curve investment ahead of it. Seventeen analysts rate the stock a consensus Buy with an average target of $257.33, roughly 39% upside, but individual targets range enormously — from $178 at JPMorgan (Neutral) to $337 at Evercore ISI (Outperform) — which tells you Wall Street itself hasn't converged on how to value a first-of-a-kind national enrichment buildout.
BWX Technologies (BWXT) is the steadier half of this pair. It trades at $172.50, down 29% from its 52-week high of $241.82, with a market cap of $15.80 billion, a far more reasonable trailing P/E of 44.7 times and forward P/E of 34.3 times, and — notably, given how few names in this sector pay one — a small dividend. Sixteen analysts rate it a consensus Buy with an average target of $234.45, about 36% upside. This is a profitable, growing, dividend-paying government contractor with real backlog growth, not a pre-commercial buildout story, and its price action is calmer accordingly (beta of 0.76 versus Centrus's 1.35).
11 What Could Go Wrong
- Federal funding for HALEU is genuinely uncertain: Centrus's own materials flag that the proposed FY2027 federal budget does not currently include further funding for HALEU cascade operations at Oak Ridge — a real, near-term risk to the smaller but faster-growing half of the dual-fuel strategy, not a hypothetical one.
- Centrus is operating with negative operating cash flow: the company posted negative operating cash flow of $16.7 million in the first half of 2026 alongside $82.2 million of Q2 capital spend — funded comfortably today by its cash balance and DOE contracts, but a real ongoing cash draw during the build-out years.
- Execution risk on first-of-a-kind manufacturing is real: building a commercial-scale centrifuge cascade is, in the company's own words, "one of the most complex machines ever invented," and delays at Piketon or Oak Ridge would directly push out the 2029 commercial-scale target.
- Valuation on Centrus leaves very little room for disappointment: an 85x trailing multiple prices in years of successful execution; any funding setback, delay, or contract loss could compress the stock sharply, and the wide dispersion in analyst targets ($178 to $337) reflects that real uncertainty.
- Both names carry government-counterparty concentration: a large share of the growth case for each company depends on continued DOE, Navy, and allied-government contracting and funding priorities remaining intact across administrations and budget cycles.
- The uranium/nuclear-components sector is thematically crowded: a broad pullback across URA and URNM shows this trade can de-rate quickly on sentiment even when individual company fundamentals are improving, and it can just as easily continue de-rating further before it turns.
12 Muffett's Take
Strategic energy security has moved from a talking point to a funded federal priority, and there are only a handful of companies actually positioned inside it. Centrus is the closest thing the U.S. has to a domestic uranium enrichment monopoly under active construction, with a $4.5 billion backlog, a $900 million DOE task order, definitive agreements with next-generation reactor developers, and a first commercial-scale centrifuge on track by year-end — funded largely without diluting shareholders. BWX Technologies is the calmer, dividend-paying anchor on the other end of the same fuel cycle, with 40% backlog growth and a management team actively sharpening its focus on nuclear and defense. Both trade meaningfully below their 52-week highs, inside a uranium-sector pullback that we think reflects sentiment catching down to a rough patch in sector-wide risk appetite rather than any deterioration in the underlying fundamentals.
We wouldn't treat these as identical bets. Centrus is the speculative, high-conviction sleeve — genuinely expensive, genuinely cash-burning during its build-out, and genuinely capable of re-rating hard in either direction on a single funding or execution headline. BWXT is the position you can hold more comfortably while that story plays out. Together, they're a reasonable way to own the actual physical rebuilding of America's nuclear fuel cycle, rather than just the sentiment around it.
